Chronic Pulmonary Hypertension Treatment Market is Expected to Accumulate a Market Value of US$ 11.4 Billion by 2033, Growing at a CAGR of 5% | Future Market Insights, Inc. Report

NEWARK, DE / ACCESSWIRE / March 15, 2023 / A report published by Future Market Insights predicts that theChronic Pulmonary Hypertension Treatment Market will reach a valuation of US$ 7 billion in 2023 and is expected to accumulate a market value of US$ 11.4 billion by registering a CAGR of 5% in the forecast period 2023 to 2033. The market is expected to witness significant growth in the coming years, driven by the increasing prevalence of pulmonary hypertension and the growing availability of effective treatment options.

Pulmonary hypertension is a condition in which the blood pressure in the pulmonary artery, which carries blood from the heart to the lungs, becomes abnormally high. This can cause the right side of the heart to work harder, leading to heart failure if left untreated. Pulmonary hypertension can be caused by a variety of factors, including genetics, heart and lung disease, and exposure to certain drugs or toxins.

Request a Sample Report @ https://www.futuremarketinsights.com/reports/sample/rep-gb-16779

One of the key drivers of the chronic pulmonary hypertension treatment market is the increasing prevalence of the disease. According to the Pulmonary Hypertension Association, an estimated 10-15% of patients with chronic obstructive pulmonary disease (COPD) and 30-40% of patients with idiopathic pulmonary fibrosis (IPF) develop pulmonary hypertension. The prevalence of pulmonary hypertension is also higher among patients with connective tissue diseases, such as scleroderma and lupus.

Another factor driving the growth of the chronic pulmonary hypertension treatment market is the availability of effective treatment options. Several medications have been approved by regulatory authorities for the treatment of pulmonary hypertension, including prostacyclins, endothelin receptor antagonists, and phosphodiesterase type 5 inhibitors. These medications work by dilating the blood vessels in the lungs, reducing the pressure in the pulmonary artery and improving blood flow.

Additionally, the growing awareness of pulmonary hypertension among healthcare professionals and patients is expected to drive the demand for effective treatment options. Pulmonary hypertension is often misdiagnosed or underdiagnosed, and increasing awareness of the disease can help ensure that patients receive timely and appropriate treatment.

Ask an Analyst @ https://www.futuremarketinsights.com/ask-question/rep-gb-16779

Key Takeaways from the Market Study

• From 2018 to 2022, the Chronic Pulmonary Hypertension Treatment market grew at a CAGR of 3.5%.
• The global Chronic Pulmonary Hypertension Treatment market is expected to grow with a 5% CAGR during 2023 to 2033.
• As of 2033, the Chronic Pulmonary Hypertension Treatment Market is expected to reach US$ 11.4 Billion.
• According to the FMI analysis, the oral route of administration accounts for the largest market share.
• North America is expected to possess 40% market share for the Chronic Pulmonary Hypertension Treatment market.
• The East & South Asia market is predicted to increase significantly throughout the forecast period, with a share of 20% during the forecast period.

"A series of international level collaborations involving healthcare stakeholders across various institutional settings are fueling further clinical trials and research studies dedicated to discovering chronic pulmonary hypertension treatment," says an FMI analyst

Request Report Customization @
https://www.futuremarketinsights.com/customization-available/rep-gb-16779

Market Competition

Key players in the market include companies such as Bayer, Attgeno AB, Cereno Scientific AB, Bial - Portela C S.A, Liquidia Technologies, Bellerophon Therapeutics, AbbVie Therapeutics, Insmed, Altavant Sciences, Lupin Pharmaceuticals, Inc., Sun Pharmaceutical Industries, Inc., Teva Pharmaceutical Industries Ltd., along with healthcare providers and technology companies among other global players.

• In June 2022, Gossamer Bio, Inc., a clinical-stage biopharmaceutical company that specializes in discovering, acquiring, developing, and commercializing therapeutics in the areas of immunology, inflammation, and oncology, announced the release of crucial preclinical data that supports the potential of seralutinib in treating pulmonary arterial hypertension (PAH). The article, titled "Inhaled Seralutinib Exhibits Potent Efficacy in Models of Pulmonary Arterial Hypertension," is available online and will be included in a future printed edition of the European Respiratory Journal, which is the premier scientific journal of the European Respiratory Society.

More Insights Available

FMI, in its new offering, presents an unbiased analysis of the global chronic pulmonary hypertension treatment market, presenting historical analysis from 2018 to 2022 and forecast statistics for the period of 2023 to 2033.

The study reveals essential insights on the basis of drug type, distribution channel, route of administration & region.

Key Segments Profiled in the Chronic Pulmonary Hypertension Treatment Industry Survey

By Drug Type:

• Endothelin Receptor Antagonists
• PDE-5 Inhibitors
• Prostacyclin Analogs
• SGC Stimulators

By Route of Administration:

• Oral
• Intravenous/Subcutaneous
• Inhalational

By Distribution Channel:

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Full Report @https://www.futuremarketinsights.com/reports/chronic-pulmonary-hypertension-treatment-market

Table of Content

1. Executive Summary | Chronic Pulmonary Hypertension Treatment Market

1.1. Global Market Outlook

1.2. Demand-side Trends

1.3. Supply-side Trends

1.4. Technology Roadmap Analysis

1.5. Analysis and Recommendations

2. Market Overview

2.1. Market Coverage / Taxonomy

2.2. Market Definition / Scope / Limitations

Explore FMI's Extensive Coverage In Healthcare Domain:

Pharmacovigilance Market Size : It is estimated that the pharmacovigilance industry will grow, from US$ 6.28 billion in 2022 to US$ 24.32 billion in 2032. Throughout the course of the anticipated period, the market is anticipated to grow at a CAGR of 13.1%, according to FMI.

Europe Viscosupplementation Market Share : Demand for efficient treatment treatments is growing as knee osteoarthritis is becoming more common. Intra-articular injections based on hyaluronic acid have emerged as one of the most popular options for treating symptomatic knee osteoarthritis.

Dental Imaging Equipment Market Opportunity : The market for dental imaging equipment is anticipated to grow from a projected valuation of US$ 2.99 Billion in 2021 to US$ 5.91 Billion by 2030, expanding at a CAGR of 7.9%.

Knee Reconstruction Devices Market Demand : By 2022, the market for knee reconstruction devices is projected to be worth US$ 8.28 billion, growing at a moderate CAGR of 4.3% between 2022 and 2032.

Vital Signs Monitoring Devices Market Growth : By 2033, the market for vital signs monitoring devices is anticipated to reach US$ 16 billion. From 2023 to 2033, the market is anticipated to expand at a CAGR of 8%. The estimated amount is $7.4 billion in 2023.

About Future Market Insights, Inc :

Future Market Insights, Inc. is an ESOMAR-certified business consulting & market research firm, a member of the Greater New York Chamber of Commerce and is headquartered in Delaware, USA. A recipient of Clutch Leaders Award 2022 on account of high client score (4.9/5), we have been collaborating with global enterprises in their business transformation journey and helping them deliver on their business ambitions. 80% of the largest Forbes 1000 enterprises are our clients. We serve global clients across all leading & niche market segments across all major industries.

Contact Us:

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware - 19713, USA
T: +1-845-579-5705
LinkedIn | Twitter | Blogs | YouTube
For Sales Enquiries: sales@futuremarketinsights.com

SOURCE: Future Market Insights, Inc.

ACCESSWIRE

News network reaching more than 1,500 media outlets in 98 countries. The newest, fastest-growing and most disruptive newswire available today.